On July 29, 2026, period-tracking company Clue publicized research using its user data suggesting that where in the menstrual cycle a COVID-19 vaccine is given is associated with how likely someone is to report side effects. The underlying paper — "Menstrual cycle phase and its association with COVID-19 vaccine outcomes among period tracking app users" — was published in npj Women's Health on June 6, 2026 (DOI 10.1038/s44294-026-00150-x), following a November 2025 medRxiv preprint. FemTech World covered the findings on July 31.

Why It Matters

This is femtech's most defensible strategic asset finally being used the way the pitch decks always promised. Cycle-tracking apps sit on longitudinal, self-reported physiological data at a scale no clinical trial can replicate — Clue, Flo and Natural Cycles collectively hold cycle histories for tens of millions of people. Converting that into peer-reviewed publication in a Nature-family journal is a different proposition from converting it into ad targeting, and it is the argument these companies need to be making right now. The timing is not incidental. This lands two weeks after the Mozilla Foundation caught period tracker Stardust sharing users' reproductive data with a third-party analytics firm, and amid ongoing post-Dobbs anxiety about menstrual data and law enforcement. The femtech data debate has been framed almost entirely as risk. Research output is the counterweight — evidence that the data has a public-health return, not just a commercial one. Expect Clue and its competitors to lean much harder on published research as reputational infrastructure. Scientifically, treat this as a signal, not a finding. Self-reported side effects from an app-using cohort carry obvious selection and reporting bias, and the infection-timing analysis is underpowered by the authors' own admission. But the mechanism is biologically plausible — estradiol is broadly immune-enhancing, progesterone broadly dampening, and women have long been observed to mount stronger antibody responses and report more side effects than men after influenza, MMR and hepatitis vaccines. If it replicates in a designed study, cycle phase becomes a variable that vaccine trials, and eventually vaccine scheduling, have to account for. That would be a genuine femtech-to-mainstream-medicine crossover.

The headline result, drawn from an analytical dataset of 1,474 Clue users: people vaccinated during the estrogen-dominant follicular phase (before ovulation) had 35% higher odds of reporting any vaccine side effect than those vaccinated during the progesterone-dominant luteal phase. Sensitivity analyses that excluded people vaccinated around menstruation produced similar results, suggesting the association is not simply menstrual or premenstrual symptoms being misattributed. Notably, follicular-phase vaccination was not associated with more severe side effects or a greater number of them — only with a higher chance of reporting any at all.

A second, weaker finding is the one to handle with tongs. Those vaccinated in the follicular phase went a median of 200 days before reporting a subsequent COVID-19 infection, versus 164 days for the luteal group — a 35-day difference. But only 82 infections were recorded across the whole sample, and the researchers explicitly flagged this as exploratory and hypothesis-generating rather than evidence that vaccine timing improves protection. The work was led by Poppy Cooper at the London School of Hygiene & Tropical Medicine and Alexandra Alvergne at the University of Montpellier, with collaborators at Oregon Health & Science University and Clue. Amanda Shea, Clue's fractional chief science officer, framed the point bluntly: "We know that immune function fluctuates across the menstrual cycle, yet it's still rarely considered in mainstream health research... we need to stop treating the menstrual cycle as background noise."

Sources

Update — 2026-08-02

Initial entry — story first created.